



ASSTON PHARMACEUTICALS LIMITED
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)

Date: 21st January, 2026

To,
BSE Limited
Listing / Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai, 400001

BSE Code: 544445
ISIN: INEOSJX01015

Sub: Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Ref: Our letter dated November 14, 2025, regarding capacity addition.

Dear Sir /Madam,

Pursuant to Regulation 30 read with the Clause B of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.: SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023, and in continuation to our said letter dated November 14, 2025, we are pleased to inform you that as per the scheduled plan, Unit (Unit II) of Asston Pharmaceuticals Limited (manufacturing Pharmaceuticals and Nutraceuticals Products) situated at Plot no W 18-A, MIDC, Addl. Ambernath, Anand Nagar Industrial area, Dist-Thane, Mumbai, Maharashtra 421501, will commence its commercial production effective from today i.e. January 21, 2026.

Please take note of the same in your record.
Thanking you

For and on behalf of the Board of Directors

Rishi Upadhaya
Company Secretary and Compliance Officer
A74324

CIN: U24304MH2019PLC324187

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi
Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com

Web: www.asstonpharmaceuticals.com